Brief: GRI Bio Continues To Drive Enrollment In Ongoing Phase 2A Study Of GRI-0621 In Idiopathic Pulmonary Fibrosis
07/05/2025 14:40
May 7 (Reuters) - GRI Bio Inc GRI.O: GRI BIO CONTINUES TO DRIVE ENROLLMENT IN ONGOING PHASE 2A STUDY OF GRI-0621 IN IDIOPATHIC PULMONARY FIBROSIS (“IPF”) Source text: ID:nGNXZv8N3 Further company coverage: GRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027